X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LIB003 (lerodalcibep) is a potential best in class, novel, small binding protein, third-generation PCSK9 inhibitor, which is being evaluated for the treatment and prevention of cardiovascular disease.
Lead Product(s): Lerodalcibep
Therapeutic Area: Cardiology/Vascular Diseases Product Name: LIB003
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: LIB Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
Under the terms of the agreement, LIB has granted Hasten the exclusive rights to develop and commercialize LIB003 (lerodalcibep), a next-generation, PCSK9 inhibitor, for patients at very high and high-risk of cardiovascular disease, in Greater China.
Lead Product(s): Lerodalcibep
Therapeutic Area: Genetic Disease Product Name: LIB003
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: LIB Therapeutics
Deal Size: $325.0 million Upfront Cash: $20.0 million
Deal Type: Licensing Agreement September 12, 2023
Details:
The proceeds will fund the future acquisitions and business development of five cardiovascular and metabolic products, including Ebrantil®, Edarbi®, Blopress®, Basen®, and Actos®. Edarbi (azilsartan medoxomil) is an angiotensin II receptor blocker, used to treat hypertension.
Lead Product(s): Azilsartan
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Edarbi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: CBC Group
Deal Size: $315.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 20, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
